免疫原性细胞死亡
癌症研究
肿瘤微环境
免疫
化学
免疫系统
程序性细胞死亡
免疫疗法
诱导剂
获得性免疫系统
细胞凋亡
抗体疗法
细胞毒性
肿瘤免疫学
先天免疫系统
免疫学
医学
细胞
生物
癌症免疫疗法
药理学
肿瘤细胞
细胞存活
作者
Xiaojie Chen,Haojia Li,Jianfei Chen,Boyang Hou,Zhaokun Tian,Wenyan Qiu,Zhiyong Yu
标识
DOI:10.3389/fphar.2026.1745590
摘要
Background: The immunosuppressive tumor microenvironment (TME) is a principal factor limiting the success of current cancer immunotherapies. Immunogenic cell death (ICD), a process whereby dying tumor cells elicit an adaptive immune response through the emission of damage-associated molecular patterns (DAMPs), offers a promising strategy to counteract this limitation. Natural products (NPs) constitute a valuable reservoir of compounds capable of triggering ICD. Purpose: This review aims to provide a comprehensive overview of ICD inducers derived from NPs, detail their molecular mechanisms of action, and explore their capacity to remodel the immunosuppressive TME. Methods: We performed a comprehensive literature search in relevant electronic databases to identify studies describing NPs-based components that stimulate characteristic ICD markers, such as surface exposure of calreticulin (CRT), and extracellular release of ATP and high mobility group box 1 (HMGB1). Results: Active components of NPs were demonstrated to initiate ICD largely via the induction of endoplasmic reticulum (ER) stress and reactive oxygen species (ROS). The consequent emission of DAMPs facilitates dendritic cell-mediated phagocytosis of tumor antigens and the priming of cytotoxic T lymphocytes. Additionally, the inflammatory milieu generated by NPs-induced ICD reprograms the TME by promoting the repolarization of macrophages to an immunostimulatory M1 phenotype and inhibiting the suppressive functions of myeloid-derived suppressor cells (MDSCs). Conclusion: Inducing ICD with NPs is a viable therapeutic strategy to potentiate anti-tumor immunity. The convergence of NPs-based ICD inducers with nanotechnology-based delivery systems offers a robust platform for the development of innovative combination regimens aimed at improving patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI